Judy Hejingdao Wu
Operationeel Directeur bij ASCLETIS PHARMA INC.
Vermogen: 14 M $ op 30-04-2024
Actieve functies van Judy Hejingdao Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ASCLETIS PHARMA INC. | Directeur/Bestuurslid | 13-03-2019 | - |
| Operationeel Directeur | - | - | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Directeur/Bestuurslid | - | - |
| Ascletis BioScience Co., Ltd. | Directeur/Bestuurslid | 01-01-2014 | - |
| Corporate Officer/Principal | 01-01-2014 | - | |
| Gannex LLC | Corporate Officer/Principal | 01-01-2021 | - |
Loopbaan van Judy Hejingdao Wu
Eerdere bekende functies van Judy Hejingdao Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Ascletis Pharmaceuticals Co., Ltd. | Corporate Officer/Principal | 01-09-2014 | 01-12-2021 |
Opleiding van Judy Hejingdao Wu
| Zhejiang University | Undergraduate Degree |
Statistieken
Internationaal
| China | 5 |
| Verenigde Staten | 3 |
Operationeel
| Director/Board Member | 3 |
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ASCLETIS PHARMA INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| Ascletis BioScience Co., Ltd. | |
| Ascletis Pharmaceuticals Co., Ltd. | |
| Gannex LLC |
- Beurs
- Insiders
- Judy Hejingdao Wu
- Ervaring
